Further research uncovered a broad spectrum of cell surface
stem cell markers (e.g., CD133, CD44, and CD24) that allow the identification of CSCs in
human solid tumors, including brain, breast,
prostate, pancreas, liver, ovary, skin, colon cancers, and melanoma (3 - 6)(Figure 1 based on 7).
In a series of lab experiments with cell lines,
human xenograft tumors in mice and primary
human prostate cancer samples, the researchers demonstrated that miR - 34a inhibits
prostate cancer
stem cells by suppressing CD44.